亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

武漢市南沖醫藥化學制造科技有限公司  

.全國，企業及個人
搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人：尹飛
  • 電話：027-88774379
  • 郵件：903224777@qq.com
  • 傳真：027-88774376
  • QQ：903224777
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 霉酚酸酯，嗎替麥考酚酯
霉酚酸酯，嗎替麥考酚酯
單價 面議對比
詢價 暫無
發貨 湖北武漢市付款后3天內
過期 長期有效
更新 2012-03-07 16:05
 
詳細信息

霉酚酸酯，嗎替麥考酚酯

用途

免疫抑制劑

英文名

Mycophenolate mofetil

CAS No.

115007-34-6

結構式

  Mycophenolate mofetil, 2-Morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-isobenzofuran-5-yl)-4-methyl-hex-4-enoate CAS #: 115007-34-6 - Chemicals from China: intermediates, biochemicals, agrochemicals, flavors, fragrants, additives, reagents, dyestuffs, pigments, suppliers.    

分子式

C23H31NO7

分子量

433.50
©2025 武漢市南沖醫藥化學制造科技有限公司 版權所有   技術支持：化工網   訪問量:34875  
 
主站蜘蛛池模板： | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |